Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is anticipated to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Price Performance

Shares of NASDAQ:ATOS opened at $0.70 on Monday. The business has a 50-day moving average of $0.79 and a two-hundred day moving average of $1.10. The firm has a market capitalization of $89.93 million, a PE ratio of -3.16 and a beta of 1.20. Atossa Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.31.

Institutional Investors Weigh In On Atossa Therapeutics

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE boosted its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 111,475 shares of the company’s stock after acquiring an additional 37,809 shares during the quarter. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent reporting period. 12.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ATOS has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a research report on Wednesday, March 26th. Ascendiant Capital Markets boosted their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.